SNCE News and Press, Science 37 Holdings Inc. From 09/08/22

RESEARCH TRIANGLE PARK, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Science 37 ® Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced the company will be participating in the upcoming Baird Global Healthcare Conference in New York. Sc...

RESEARCH TRIANGLE PARK, N.C. and BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced a partnership with leading digital health company, NuvoAir, to incorporate remote collection of respirator...

RESEARCH TRIANGLE PARK, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) today announced new patient relationship management and contact center technology to improve patient engagement, leading to faster patient recruitment and greater enrollment conversion r...

Science 37 ( NASDAQ: SNCE ) Syapse said they are collaborating to deploy proprietary real-world data intelligence and analytics to help identify suitable patients for oncology clinical trials, thus helping speed up the enrollment process. "By partnering with Syapse, we...

RESEARCH TRIANGLE PARK, N.C. and SAN FRANCISCO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, and Syapse®, a leading real-world evidence company, today announced a partnership to deploy proprietary real-wo...

Science 37 Holdings, Inc. (SNCE) Q2 2022 Earnings Conference Call August 11, 2022 08:30 ET Company Participants Caroline Paul - Investor Relations David Coman - Chief Executive Officer Mike Zaranek - Chief Financial Officer Conference Call Participants ...

The following slide deck was published by Science 37 Holdings, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Science 37 Holdings, Inc. 2022 Q2 - Results - Earnings Call Presentation

Science 37 press release ( NASDAQ: SNCE ): Q2 GAAP EPS of -$0.05 beats by $0.19 . Revenue of $19.3M (+53.8% Y/Y) misses by $0.2M . Net bookings were $25.4M for the quarter ended June 30, 2022, compared to $44.1M for the same period in 2021. Adjusted EB...

RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results for the quarter ended June 30, 2022. "We made meaningful strid...

RESEARCH TRIANGLE PARK, N.C., July 28, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report second quarter 2022 financial results before the market opens on Thursday, August 11, 2022. Company mana...